T. Rowe Price Associates, Inc. 13D and 13G filings for Ionis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-08-10 2:56 pm Sale |
2022-07-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Associates, Inc. | 4,808,770 3.300% |
-9,541,690 (-66.49%) |
Filing |
| 2022-04-11 11:13 am Purchase |
2022-03-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Associates, Inc. | 14,350,460 10.100% |
1,860,180 (+14.89%) |
Filing |
| 2022-02-14 2:34 pm Sale |
2021-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Associates, Inc. | 12,490,280 8.800% |
-624,687 (-4.76%) |
Filing |
| 2021-02-16 12:23 pm Purchase |
2020-12-31 | 13G | Ionis Pharmaceuticals, Inc. IONS |
T. Rowe Price Associates, Inc. | 13,114,967 9.300% |
13,114,967 (New Position) |
Filing |